Author:
Stellbrink Hans-Jürgen,Reynes Jacques,Lazzarin Adriano,Voronin Eugene,Pulido Federico,Felizarta Franco,Almond Steve,Clair Marty St,Flack Nancy,Min Sherene
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Infectious Diseases,Immunology,Immunology and Allergy
Reference7 articles.
1. Integrase inhibitors in the treatment of HIV-1 infection.;Powderly;J Antimicrob Chemother,2010
2. Activity of elvitegravir, a once-daily integrase inhibitor, against resistant HIV type 1: results of a phase 2, randomized, controlled, dose-ranging clinical trial.;Zolopa;J Infect Dis,2010
3. HIV-1 integrase inhibitor resistance and its clinical implications.;Blanco;J Infect Dis,2011
4. Antiviral activity, safety, and pharmacokineticspharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults.;Min;AIDS,2011
5. In vitro antiretroviral properties of SGSK1349572, a next-generation HIV integrase inhibitor.;Kobayashi;Antimicrob Agents Chemother,2011